Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2017

View Archived Issues

AbbVie studies SC-007 in advanced colorectal and gastric cancers

Gq protein inhibition induces bronchorelaxation in asthma models

Zhejiang Vimgreen Pharma identifies novel PI3Kdelta inhibitors

New PI3K inhibitors synthesized at Bayer

Celyad reports initial results from THINK trial

Janssen divulges novel protein arginine N-methyltransferase 5 inhibitors

Vical's VL-2297 possibly eligible for limited use indication approval in U.S.

Blade Therapeutics patents novel calpain inhibitors

Transgene and Randox to develop multifunctional oncolytic immunotherapies

Raze Therapeutics discovers novel 3-PGDH inhibitors

AbbVie's Humira given orphan drug status for hidradenitis suppurativa in Japan

Ritter Pharmaceuticals raises funds for phase III program for RP-G28

Trispecific antibodies show protection against SHIV in macaques

Pulmatrix's Pulmazole receives second QIDP designation

Gilead Sciences acquisition of Kite Pharma complete

Ultragenyx Pharmaceutical, Dimension Therapeutics enter definitive merger agreement

X-Chem and Bayer expand drug discovery collaboration

Spero Therapeutics' SPR-741 well-tolerated in phase I study

RedHill Biopharma announces topline results from phase II study of Bekinda in IBS-D

Emergent BioSolutions completes acquisition of raxibacumab from GSK

Nimbus Therapeutics and Celgene begin alliance to develop immunology drugs

Saniona reaches third milestone under Michael J. Fox Foundation grant

New MAPT gene mutations identified in families with tauopathies

Iclaprim meets primary endpoint in phase III REVIVE-2 study

DiscGenics cleared to begin clinical testing of IDCT in U.S.

ImmunoMet Therapeutics commences phase I study of OXPHOS inhibitor

Boehringer Ingelheim applies for approval of empagliflozin/linagliptin in Japan

Fibrinogen-like protein 1 linked to obesity

FDA lifts clinical hold on phase IIb study of ATL-1102 in MS